| Added by | standudu |
|---|---|
| Group name | EquipeCTCS |
| Item Type | Journal Article |
| Title | Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database |
| Creator | Mailliez et al. |
| Author | Audrey Mailliez |
| Author | Amelie Lusque |
| Author | Olivier Caron |
| Author | Luc Cabel |
| Author | Anthony Goncalves |
| Author | Marc Debled |
| Author | Laurence Gladieff |
| Author | Jean-Marc Ferrero |
| Author | Thierry Petit |
| Author | Marie Ange Mouret-Reynier |
| Author | Jean-Christophe Eymard |
| Author | Christelle Levy |
| Author | Lionel Uwer |
| Author | Marianne Leheurteur |
| Author | Isabelle Desmoulins |
| Author | Thomas Bachelot |
| Author | Gaëtane Simon |
| Author | William Jacot |
| Author | Suzette Delaloge |
| Abstract | The outcomes and best treatment strategies for germline BRCA1/2 mutation (gBRCAm) carriers with metastatic breast cancer (MBC) remain uncertain. We compared the overall survival and the first line progression free survival (PFS1) of patients with a gBRCAm identified at initiation of first-line treatment with those of BRCA wild-type (WT) and not-tested (NT) individuals in the ESME real-world database of MBC patients between 2008 and 2016 (NCT03275311). Among the 20?624 eligible patients, 325 had a gBRCAm, 1138 were WT and 19?161 NT. Compared with WT, gBRCAm carriers were younger, and had more aggressive diseases. At a median follow-up of 50.5 months, median OS was 30.6 (95%CI: 21.9-34.3), 35.8 (95%CI: 32.2-37.8) and 39.3 months (95% CI: 38.3-40.3) in the gBRCAm, WT and NT subgroups, respectively. Median PFS1 was 7.9 (95%CI: 6.6-9.3), 7.8 (95%CI: 7.3-8.5) and 9.7 months (95%CI, 9.5-10.0). In the multivariable analysis conducted in the whole cohort, gBRCAm status had however no independent prognostic impact on OS and PFS1. Though, in the triple-negative subgroup, gBRCAm patients had better OS and PFS1 (HR vs WT = 0.76; 95%CI: 0.60-0.97; P = .027 and 0.69; 95% CI: 0.55-0.86; P = .001, respectively). In contrast, in patients with HR+/HER2 negative cancers, PFS1 appeared significantly and OS non significantly lower for gBRCAm carriers (PFS1: HR vs WT = 1.23; 95%CI: 1.03-1.46; P = .024; OS:HR = 1.22, 95% CI: 0.97-1.52, P = .089). In conclusion, gBRCA1/2 status appears to have divergent survival effects in MBC according to IHC subtype. |
| Publication | International Journal of Cancer |
| Volume | 152 |
| Issue | 5 |
| Pages | 921-931 |
| Date | 2023-03-01 |
| Journal Abbr | Int J Cancer |
| Language | eng |
| DOI | 10.1002/ijc.34304 |
| ISSN | 1097-0215 |
| Library Catalog | PubMed |
| Extra | PMID: 36161271 PMCID: PMC10092337 |
| Tags | BRCA1 Protein, Breast Neoplasms, clinic, Female, germline BRCA mutation, Humans, metastatic breast cancer, Prognosis, Progression-Free Survival, real world |
| Date Added | 2023/10/16 - 15:34:46 |
| Date Modified | 2023/10/16 - 17:34:08 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
